aptevo therapeutics (nasdaq: apvo): advancing bispecific immunotherapies in oncology
Published 1 day ago • 31 plays • Length 0:31Download video MP4
Download video MP3
Similar videos
-
9:49
aptevo therapeutics - focus on novel immuno-oncology therapeutics
-
0:19
reviva: developing next-generation therapies for diseases with significant unmet needs
-
0:19
reviva: developing next-generation therapies for diseases with significant unmet needs
-
0:31
can-fite biopharma: developing treatments for liver cancer
-
27:02
this week on redchip tv: sixty degree pharma (nasdaq: sxtp) & reviva pharmaceuticals (nasdaq: rvph)
-
21:32
bispecific antibodies for t‐cell redirection therapy
-
4:44
context therapeutics ctim-76 bispecific antibody preclinical data presented at aacr annual meeting
-
4:55
are there any bispecific antibodies that are fda approved?
-
14:59
new approaches to prevent adverse complement activation: implications for nanomedicine
-
15:33
engineering bispecific antibody targets for novel arsenal in immune therapy - sabpa 2022
-
1:58
reviva: major breakthrough for mental health and schizophrenia
-
0:38
nano-sized particles for targeted delivery of therapeutics
-
39:33
aviptadil
-
19:26
aytu biopharma (nasdaq: aytu) | gcff virtual 2024 – healthcare investment conference (asia pacific)
-
0:16
revolutionizing rare disease treatment: introducing soligenix's breakthrough hybryte™
-
14:11
capsida biotherapeutics
-
4:30
covid-19 therapeutic treatments and the path of variants